New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Heatwurx Inc. (PCSA) vs Skye Bioscience, Inc. (SKYE)

Heatwurx Inc. and Skye Bioscience, Inc. are both Biotechnology companies. Heatwurx Inc. and Skye Bioscience, Inc. are of similar size ($4.8M and $4.6M). Across the 10 metrics below, Heatwurx Inc. leads on 6 and Skye Bioscience, Inc. on 4.

Valuation

Metric PCSA SKYE Biotechnology median
P/E n/m n/m 8.26
P/S 37.91 13.30 9.20
P/B n/m 2.92 2.09
Price to free cash flow n/m n/m 24.49
EV/EBITDA 0.90 n/m 0.67
EV/Sales (1,326.40) 18.03 9.05
Earnings yield (3,520.03%) (948.26%) (34.24%)
Free cash flow yield (298.72%) (759.13%) (24.77%)

Profitability

Metric PCSA SKYE Biotechnology median
Gross margin 0.00% 68.04% 70.18%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 220.06% (220.31%) (51.58%)
Return on assets (203.76%) (162.38%) (45.91%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric PCSA SKYE Biotechnology median
Revenue growth (TTM) (34.50%) — 7.20%
EPS growth (last fiscal year) 89.29% (93.15%) 29.04%
Revenue growth, 5-year CAGR — — 9.48%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric PCSA SKYE Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 97.70 1.36 4.83
Net debt to EBITDA 0.40 0.45 1.01

Dividend

Metric PCSA SKYE Biotechnology median
Dividend yield — — 0.40%
Payout ratio — — —

Size

Metric PCSA SKYE Biotechnology median
Market cap 4.76m 4.56m 155.23m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack